Evidence map›Paper›PMID 40639419›Full record

ReviewJournal of child psychology and psychiatry, and allied disciplines2025

Research Review: What we have learned about the endocannabinoid system in developmental psychopathology.

Ryann C Tansey, Marc D Ferger, Hilary A Marusak, Leah M Mayo

Abstract readReview
In one paragraph

Review in Journal of child psychology and psychiatry, and allied disciplines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ryann C TanseyDepartment of Psychiatry, Mathison Centre for Mental Health Research and Education, and Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.ORCID 0000-0002-6865-5893
Marc D FergerDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Hilary A MarusakDepartment of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA.
Leah M MayoDepartment of Psychiatry, Mathison Centre for Mental Health Research and Education, and Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe endocannabinoid (eCB) system, the primary target of cannabis, has gained significant attention as a potential novel therapeutic approach for treating a range of psychiatric disorders characterized by dysregulation of stress, emotion, and social behavior. The use of cannabis itself as a pharmacotherapeutic in children and adolescents is limited due to various constraints, including legal status, stigma, and real or perceived negative side effects. Thus, compounds that target the eCB system without the notable unwanted effects of cannabis may offer a more viable approach for developing populations.

methodsIn this narrative review, we provide an overview of the eCB system, summarizing its function throughout development and its potential contribution to psychopathology in children and adolescents. We highlight evidence of its behavioral role and the dysregulation of this system in various psychiatric disorders. Finally, we summarize current investigations into pharmacological and nonpharmacological therapeutic interventions designed to target the eCB system.

conclusionsThe eCB system may offer an innovative target for treatments of various psychiatric disorders in child and adolescent populations. However, more research is needed to understand the nuanced developmental trajectory of this system and to determine whether existing compounds are safe and effective for use in these populations.

Indexed as

EndocannabinoidsMental DisordersNeurodevelopmental DisordersAdolescentChildHumansEndocannabinoids2‐arachidonoylglycerolanandamidedevelopmentEndocannabinoidpsychopathology

Identifiers

PMID40639419
PMCPMC12626183

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.